Thursday, 30 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Is DaVita Stock Underperforming the Nasdaq?
Economy

Is DaVita Stock Underperforming the Nasdaq?

Last updated: September 25, 2025 4:30 am
Share
Is DaVita Stock Underperforming the Nasdaq?
SHARE

DaVita Inc.: An Overview of Market Performance and Future Prospects

Valued with a market capitalization of $9.4 billion, DaVita Inc. (DVA) stands as a key provider of kidney dialysis services catering to patients experiencing chronic kidney failure. Based out of Denver, Colorado, this healthcare entity not only offers various dialysis services, including outpatient, inpatient, and home-based hemodialysis treatments, but also provides clinical laboratory services.

In the financial markets, companies with a valuation of $2 billion or higher are typically categorized as “mid-cap stocks,” and DaVita fits this classification perfectly, boasting a market cap that highlights its significant size, influence, and dominance within the medical care facilities sector. The strength of DaVita lies in its expansive network of dialysis centers situated across the United States, which positions the company to effectively meet the needs of an ever-expanding population of patients diagnosed with chronic kidney disease.

Recent Developments in DaVita’s Market Performance

Despite its strong market presence, DaVita’s stock performance has shown a notable decline. The company has experienced a 27% drop from its 52-week high of $179.60 reached on January 31. Over the past three months, shares of DVA have fallen by 4.2%, significantly underperforming compared to the Nasdaq Composite’s ($NASX) impressive 17.2% gain during the same period.

Furthermore, in the longer-term perspective, DVA’s stock has decreased by 20% over the preceding 52 weeks, an underperformance when contrasted with a 27% increase in the Nasdaq index within the same timeframe. Year-to-date, shares of DVA have declined by 12.3%, whereas the Nasdaq has risen by 18%.

To substantiate its bearish trend, DaVita has been trading below its 200-day moving average since mid-February, with minor fluctuations. Additionally, it has remained under the 50-day moving average since late July.

See also  New inflation reading creates dilemma for Fed over cutting rates in September

www.barchart.com

On August 5, DaVita announced its Q2 results, leading to a steep decline in share prices of more than 9% in subsequent trading. The company reported total revenue growth of 6.1% year-over-year, reaching $3.4 billion, driven by a 4.8% increase in dialysis patient service revenues compared to the same quarter of the previous year. Its adjusted earnings per share (EPS) surged by 47.5% from the prior quarter, reaching $2.95, thanks to significant margin expansion. However, the operating cash flow took a sharp downturn, plummeting 59.4% year-over-year to $324 million, and free cash flow reiterated the trend, falling 76% to $157 million, which heightened investor apprehension.

It is worth noting that DaVita has also lagged behind its primary competitor, Fresenius Medical Care AG (FMS), which has rebounded by 26.7% over the last 52 weeks and enjoyed a 13.5% increase on a year-to-date basis.

Analysts’ Outlook

Considering DaVita’s recent struggles, analysts have adopted a cautious approach regarding its future performance. The stock carries a consensus rating of “Hold” from nine analysts covering it, with a mean price target of $153.57, indicating a potential upside of 17.1% from its current trading levels.


On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data presented here are for informational purposes only. This article was initially published on Barchart.com.

TAGGED:DaVitaNasdaqStockunderperforming
Share This Article
Twitter Email Copy Link Print
Previous Article Brooklyn Beckham Breaks Silence on Family Feud With Parents and Brothers Brooklyn Beckham Breaks Silence on Family Feud With Parents and Brothers
Next Article Rep. Dan Crenshaw Not Buying Jimmy Kimmel's 'New Brand of Gaslighting' Rep. Dan Crenshaw Not Buying Jimmy Kimmel's 'New Brand of Gaslighting'
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

S&P 500 record fueled by earnings strength, easing tariff fear

After a period of turmoil and uncertainty surrounding tariffs and trade policy, investors have shifted…

June 28, 2025

New COVID-19 Variant NB.1.8.1 Causes Surge In China, Spreading In U.S.

The emergence of the NB.1.8.1 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…

May 25, 2025

Celebrating President Trump’s Incredible First 100 Days – The White House

In a striking display of ambition, President Donald J. Trump claims to have achieved more…

April 29, 2025

Apple iPhone 18 Release Date, Price & Specs Rumours

The anticipation for the next generation of Apple's flagship phone, the iPhone 18 series, is…

February 7, 2025

Explaining the lost generation of footballers who came after Messi and Ronaldo

The Ballon d'Or is the most prestigious individual award in men's football, and the upcoming…

September 17, 2024

You Might Also Like

Fed’s Standing Repo Facility hits record high as policy meeting outcome looms
Economy

Fed’s Standing Repo Facility hits record high as policy meeting outcome looms

October 30, 2025
BofA Raises PT on Embraer (ERJ) to  Following Investor Day
Economy

BofA Raises PT on Embraer (ERJ) to $70 Following Investor Day

October 30, 2025
What To Expect From Micron Technology’s Report
Economy

What To Expect From Micron Technology’s Report

October 30, 2025
Alluvial Capital Management’s Views on FitLife Brands (FTLF)
Economy

Alluvial Capital Management’s Views on FitLife Brands (FTLF)

October 30, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?